Tüdőrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

5721 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spanyolország· EU contribution 262 393 EUR· until 2030. febr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Svájc· EU contribution 1 874 590 EUR· until 2032. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 216 240 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 426 534 EUR· until 2030. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting selenocysteine metabolism as a novel vulnerability in refractory non-small-cell lung cancer (SelenoResist)

  Universitat Wien· Wien, Ausztria· EU contribution 214 345 EUR· until 2028. nov.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spanyolország· EU contribution 150 000 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Specific delivery of active biomolecules to treat lung cancer (SafeDelivery)

  Fundacio Centre de Regulacio Genomica· Barcelona, Spanyolország· EU contribution 3 323 826 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Delivering a '1-2 punch' to RAS-driven cancers (RAS-PUNCH)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2028. okt.

10 of 66 running projects, newest first. Listed amounts together: 224,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

  NCT05642195· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Revisions to eligibility/design being made prior to enrollment of first participants.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT06694454· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  NCT04402788· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Scheduled Interim Monitoring”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

  NCT06083454· William Zeitler· Frissítve: 2026. nov. 10.

  “funding change”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· National Cancer Institute (NCI)· Frissítve: 2026. nov. 10.

  “Withdrawal of tazemetostat supply led to early study closure.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Novartis Pharmaceuticals· Frissítve: 2026. nov. 6.

  “Business reasons and not based on any safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Frissítve: 2026. nov. 5.

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Nutritional Supplement to Support People With Non-small Cell Lung Cancer

  NCT04175769· AHS Cancer Control Alberta· Frissítve: 2026. nov. 3.

  “Unreliable supply of investigational product.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

  NCT07353957· Genmab· Frissítve: 2026. nov. 2.

  “This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any safety concern.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  HEARTS Trial for Thoracic Cancers

  NCT07132918· University of Wisconsin, Madison· Frissítve: 2026. okt. 30.

  “Funding issues”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

  NCT04665739· National Cancer Institute (NCI)· Forrás

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Boehringer Ingelheim· Forrás

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Forrás

• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

  NCT04310020· National Cancer Institute (NCI)· Forrás

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Forrás

• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT03088540· Regeneron Pharmaceuticals· Forrás

• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

  NCT05198830· National Cancer Institute (NCI)· Forrás

• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· National Cancer Institute (NCI)· Forrás

• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· National Cancer Institute (NCI)· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients.

  Anal Methods, 2026. okt.

• CHAI-sEV: A Programmable Hairpin-Driven Cas9 Platform with AI Integration for Dual-Protein Profiling and Intelligent Classification of Tumor-Derived Small Extracellular Vesicles.

  Anal Chem, 2026. szept.

• Genome-wide CRISPR screen reveals CGS-15943 induced heme-dependent cell death mediated by aryl hydrocarbon receptor in lung cancer cells.

  Apoptosis, 2026. aug.

• CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerability.

  Mol Cancer, 2026. aug.

• A cascaded signal amplification strategy combining Au@Cu2O core-shell nanozymes and CRISPR-Cas12a self-cycling for ultrasensitive colorimetric detection of miRNA-21.

  Anal Chim Acta, 2026. júl.

• Photo-switchable CRISPR electrochemical system enables de-interferential biosensing signal output.

  Biosens Bioelectron, 2026. júl.

• Targeting RAB27A-mediated small extracellular vesicle secretion via CRISPR-Cas9 negatively affects proliferation and metastasis in both in vitro and in vivo SCLC models.

  Cancer Gene Ther, 2026. júl.

• CRISPRi-Mediated Epigenetic Suppression of TERT Reduces Cell Growth in Non-Small-Cell Lung Cancer Cells.

  Cells, 2026. jún.

• Endonuclease-Assisted Selective Exponential Amplification for Ultrasensitive Enrichment and Detection of Low-Abundance Mutant Alleles in Lung Cancer.

  J Mol Diagn, 2026. jún.

• Machine Learning for CRISPR-Based Diagnostics.

  Int J Mol Sci, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.